Adverum biotechnology reports grant grants under the base of Nasdaq base 5635 (C) (4) – Adverum Biotechnologies (Nasdaq: Advm)

Redwood City, California, February 28, 2025 (Globe Newswire) – Adverum Biotechnologys, Inc. Advm Today, the compensation committee of the Adverum Board of Directors has awarded the motivation prizes consisting of unqualified stock options to buy 44,380 shares of regular shares and restricted stock units (RSU) compared to 22,790 shares from joint shares to 5 new employees under the ADVERUM 2017 stimulation plan. The Competion Committee of the Adverum Board of Directors agreed to the awards as articles urging Employment of new employees according to the NASDAQ 5635 (c) list (4).

Each shares option has an exercise price per share equal to $ 4.20 per share, and the closing price of Adverum in the date of the grant, and it will rise over a period of four years, with 25 % of the shares on the first anniversary of the date of the start of the applicable water^Y Through the monthly stock balance, more than 36 months later, according to the continuous service relationship for the new employee with Adverum through the applicable registration dates. Each of the RSU units will continue for three years, with a third (1/3^roadAmong the shares that start on all the anniversary of the date of the start of the inserted folklore, according to the continuous relationship of the new employee with Adverum through the applicable registration dates. Prizes are subject to the terms and conditions of an adverum incitement plan for 2017 and the terms and conditions of the applicable prizes agreement covering the grant.

About Adverum Biotechnologies

Adverum Biotechnologies Advm It is a clinical stage that aims to create genetic therapy to maintain a lifelong eyesight in the very prevailing eye diseases with the aspirations of developing functional treatments to restore vision and prevent blindness. Take advantage of the capacity of its IVTREAL platform (IVT), Adverum develops solid and objective treatments, designed to deliver them into doctors ’offices, to eliminate the need for frequent eye injection to treat these diseases. Adverm evaluates the new genetic treatment candidate, IXOberogene Soroparvove (IXO-VEC, previously referred to as AdVM-022), as IVT injection for one time for patients with vascular or wet segral degeneration. In addition, by overcoming the challenges associated with the current treatment forms of exhausted eye diseases, Adverum aspires to transform the level of care, maintain vision, and create a deep societal effect around the world. For more information, please visit www.adverum.com.

Inquiries:

Adverum investor relationships

Email: Ir@adverum.com